Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.

NCT07933848 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 17, 2026
Completion date
May 27, 2028
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults, renal impairment

Arms

As registered; 3 arms.

  • Moderate Renal Impairment (Cohort 1) ExperimentalPrifetrastat

    Prifetrastat administered by mouth as a single dose in participants with moderate renal impairment (eGFR = 30-59 mL/min).

  • Severe Renal Impairment (Cohort 2) ExperimentalPrifetrastat

    Prifetrastat administered by mouth as a single dose in participants with severe renal impairment (eGFR \< 30 mL/min).

  • Normal Renal Function (Cohort 3) Active comparatorPrifetrastat

    Prifetrastat administered by mouth as a single dose in participants with normal renal function (eGFR ≥ 90 mL/min).

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
  • Maximum Observed Plasma Concentration (Cmax) of Prifetrastat Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose

Lead sponsor's other trials

Pfizer, most recent start first.

Similar trials

Same condition (Renal Insufficiency) and phase, most recent start first.